(VIANEWS) – Bruker Corporation (BRKR), The Pennant Group (PNTG), Vertex Pharmaceuticals (VRTX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Bruker Corporation (BRKR)
19.1% sales growth and 27.91% return on equity
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Earnings Per Share
As for profitability, Bruker Corporation has a trailing twelve months EPS of $2.1.
PE Ratio
Bruker Corporation has a trailing twelve months price to earnings ratio of 35.62. Meaning, the purchaser of the share is investing $35.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.91%.
Moving Average
Bruker Corporation’s value is under its 50-day moving average of $76.85 and above its 200-day moving average of $68.19.
Sales Growth
Bruker Corporation’s sales growth is 10.1% for the present quarter and 19.1% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Bruker Corporation’s EBITDA is 4.43.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.2%, now sitting on 2.62B for the twelve trailing months.
2. The Pennant Group (PNTG)
12.1% sales growth and 6.54% return on equity
The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors, who are independent or who require some support. As of December 31, 2021, the company operated 88 home health and hospice agencies, and 54 senior living communities with 4127 Senior Living units in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.
Earnings Per Share
As for profitability, The Pennant Group has a trailing twelve months EPS of $0.26.
PE Ratio
The Pennant Group has a trailing twelve months price to earnings ratio of 47.69. Meaning, the purchaser of the share is investing $47.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.54%.
3. Vertex Pharmaceuticals (VRTX)
10.3% sales growth and 25.73% return on equity
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $12.51.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 27.79. Meaning, the purchaser of the share is investing $27.79 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.73%.
Yearly Top and Bottom Value
Vertex Pharmaceuticals’s stock is valued at $347.66 at 06:22 EST, below its 52-week high of $354.46 and way above its 52-week low of $243.17.
Moving Average
Vertex Pharmaceuticals’s worth is above its 50-day moving average of $333.40 and way higher than its 200-day moving average of $307.79.
Sales Growth
Vertex Pharmaceuticals’s sales growth is 10.2% for the ongoing quarter and 10.3% for the next.
Volume
Today’s last reported volume for Vertex Pharmaceuticals is 406028 which is 66.25% below its average volume of 1203130.
4. Addus HomeCare Corporation (ADUS)
7.1% sales growth and 8.14% return on equity
Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. It operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. As of December 31, 2021, the company served consumers through 206 offices located in 22 states. Addus HomeCare Corporation was founded in 1979 and is based in Frisco, Texas.
Earnings Per Share
As for profitability, Addus HomeCare Corporation has a trailing twelve months EPS of $3.04.
PE Ratio
Addus HomeCare Corporation has a trailing twelve months price to earnings ratio of 30.42. Meaning, the purchaser of the share is investing $30.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.14%.
Moving Average
Addus HomeCare Corporation’s worth is below its 50-day moving average of $96.71 and below its 200-day moving average of $100.79.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 11% and 11.7%, respectively.
Sales Growth
Addus HomeCare Corporation’s sales growth is 8% for the current quarter and 7.1% for the next.
5. Limestone Bancorp (LMST)
5.7% sales growth and 14.21% return on equity
Limestone Bancorp, Inc. operates as the bank holding company for Limestone Bank, Inc. that provides a range of commercial and personal banking products and services. The company offers deposit products, including savings, interest checking, and money market accounts, as well as fixed rate certificates with varying maturities. It also provides commercial loans for equipment purchases, working capital, and other financing needs of business enterprises; and commercial real estate loans that comprise loans on properties occupied by borrowers and tenants, as well as construction and development loans secured by land under development, or homes and commercial buildings under construction. In addition, the company offers residential real estate loans; consumer loans; agriculture loans secured by livestock, crops, and equipment; and other loans, including loans to municipalities, loans secured by stock, and overdrafts. Further, it provides drive-through banking facilities, automatic teller machines, personalized checks, credit and debit cards, electronic funds transfers through ACH services, domestic and foreign wire transfers, and loan and deposit sweep accounts; and curbside banking, night depository, internet and mobile banking, treasury management, remote deposit, cash management, and vault services. The company primarily serves communities and small to medium-sized businesses, the owners and employees of these businesses, and other executives and professionals. It operates 20 banking offices in 14 counties in Kentucky. The company was formerly known as Porter Bancorp, Inc. and changed its name to Limestone Bancorp, Inc. in May 2018. Limestone Bancorp, Inc. was founded in 1902 and is headquartered in Louisville, Kentucky.
Earnings Per Share
As for profitability, Limestone Bancorp has a trailing twelve months EPS of $2.48.
PE Ratio
Limestone Bancorp has a trailing twelve months price to earnings ratio of 9.44. Meaning, the purchaser of the share is investing $9.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.21%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.1%, now sitting on 59.02M for the twelve trailing months.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Feb 2, 2023, the estimated forward annual dividend rate is 0.2 and the estimated forward annual dividend yield is 0.85%.
Yearly Top and Bottom Value
Limestone Bancorp’s stock is valued at $23.42 at 06:22 EST, way below its 52-week high of $27.71 and way higher than its 52-week low of $18.32.
